Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide + dexamethasone with rituximab or bortezomib for newly diagnosed lymphoplasmacytic lymphoma / Waldenström macroglobulinemia
ChiCTR-IIR-16008400Phase 3Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bortezomib, rituximab, cyclophosphamide and dexamethasone in Lymphoplasmacytic Lymphoma (LPL) and Waldenström macroglobulinemia (WM) (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Overall response rate. Started May 2016; status: recruiting.
02
Drugs
bortezomibrituximabcyclophosphamidedexamethasone
03
Conditions
Lymphoplasmacytic Lymphoma (LPL)Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on ChiCTR-IIR-16008400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-16008400.